{
  "paper_id": "PMC5488108",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488108/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1.",
      "caption": "Disposition of patients (enrolled set).a\nEAP expanded access program, AE adverse event. a Enrolled set included all patients who signed the informed consent. b Transition to commercially available drug",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f47/5488108/53531b8dcd5e/40487_2017_43_Fig1_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f47/5488108/53531b8dcd5e/40487_2017_43_Fig1_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f47/5488108/53531b8dcd5e/40487_2017_43_Fig1_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f47/5488108/53531b8dcd5e/40487_2017_43_Fig1_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f47/5488108/53531b8dcd5e/40487_2017_43_Fig1_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC5488108/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5f47/5488108/53531b8dcd5e/40487_2017_43_Fig1_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Safety was assessed descriptively.Statistical Analysis\nExploratory, descriptive analyses of demographic, safety, and efficacy data were planned based on the treated set (all patients who were dispensed medication and were documented to have taken ≥1 afatinib dose), with two subgroups divided by previous TKI exposure.Results\nPatients\nFrom July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Safety was assessed descriptively.Statistical Analysis\nExploratory, descriptive analyses of demographic, safety, and efficacy data were planned based on the treated set (all patients who were dispensed medication and were documented to have taken ≥1 afatinib dose), with two subgroups divided by previous TKI exposure.Results\nPatients\nFrom July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Safety was assessed descriptively.Statistical Analysis\nExploratory, descriptive analyses of demographic, safety, and efficacy data were planned based on the treated set (all patients who were dispensed medication and were documented to have taken ≥1 afatinib dose), with two subgroups divided by previous TKI exposure.Results\nPatients\nFrom July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Safety was assessed descriptively.Statistical Analysis\nExploratory, descriptive analyses of demographic, safety, and efficacy data were planned based on the treated set (all patients who were dispensed medication and were documented to have taken ≥1 afatinib dose), with two subgroups divided by previous TKI exposure.Results\nPatients\nFrom July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Safety was assessed descriptively.Statistical Analysis\nExploratory, descriptive analyses of demographic, safety, and efficacy data were planned based on the treated set (all patients who were dispensed medication and were documented to have taken ≥1 afatinib dose), with two subgroups divided by previous TKI exposure.Results\nPatients\nFrom July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Safety was assessed descriptively.Statistical Analysis\nExploratory, descriptive analyses of demographic, safety, and efficacy data were planned based on the treated set (all patients who were dispensed medication and were documented to have taken ≥1 afatinib dose), with two subgroups divided by previous TKI exposure.Results\nPatients\nFrom July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Safety was assessed descriptively.Statistical Analysis\nExploratory, descriptive analyses of demographic, safety, and efficacy data were planned based on the treated set (all patients who were dispensed medication and were documented to have taken ≥1 afatinib dose), with two subgroups divided by previous TKI exposure.Results\nPatients\nFrom July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Safety was assessed descriptively.Statistical Analysis\nExploratory, descriptive analyses of demographic, safety, and efficacy data were planned based on the treated set (all patients who were dispensed medication and were documented to have taken ≥1 afatinib dose), with two subgroups divided by previous TKI exposure.Results\nPatients\nFrom July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Results\nPatients\nFrom July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients\nFrom July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "From July 2012 to March 2014, 371 patients were enrolled and 322 patients were treated with ≥1 afatinib dose (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 1,
    "claims_count": 11,
    "images_downloaded": 1,
    "tables_filtered": 120
  }
}